| Benign Prostatic Hyperplasia (BPH) is a noncancerous enlargement of the prostate gland that commonly occurs in older men. - Increased DHT levels in prostatic tissue are associated with hyperplasia. - An imbalance in IGF signaling might contribute to abnormal growth. - Targeted therapies (such as 5α-reductase inhibitors and α-blockers). |
| 4622- | Bor, | Boron Level in the Prostate of the Normal Human: A Systematic Review |
| - | Review, | BPH, | NA |
| 4621- | Bor, | Boron |
| - | Review, | BPH, | NA |
| 761- | Bor, | Prevalence of Prostate Cancer in High Boron-Exposed Population: A Community-Based Study |
| - | Study, | BPH, | NA |
| 3473- | MF, | Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia |
| - | Human, | BPH, | NA |
| 3328- | SIL, | Modulatory effect of silymarin on inflammatory mediators in experimentally induced benign prostatic hyperplasia: emphasis on PTEN, HIF-1α, and NF-κB |
| - | in-vivo, | BPH, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:86 Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid